Sleep & Circadian Rhythm Research links this combination with improved GH pulses during nocturnal cycles and better sleep structure
References Jastreboff AM, et al, Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, New England Journal of Medicine, 2023 Bajaj HS, et al, Efficacy and Safety of Retatrutide in Type 2 Diabetes, TRANSCEND-T2D-1, a Phase 3 Trial, The Lancet, 2026 Giblin K, Kaplan LM, Somers VK, et al, Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis, Rationale and Design of the TRIUMPH Registrational Clinical Trials, Diabetes, Obesity and Metabolism, 2026 ClinicalTrials.gov, TRIUMPH-1 trial registry entry, NCT05929066 Eli Lilly and Company, TRIUMPH-1 Phase 3 topline results announcement, May 2026 Eli Lilly and Company, TRIUMPH-4 Phase 3 trial results announcement, December 2025 Eli Lilly and Company, TRANSCEND-T2D-1 Phase 3 topline results announcement, March 2026 Central Drugs Standard Control Organisation, Subject Expert Committee meeting record on retatrutide Phase 3 trial permission, 2024 Medically reviewed by This guide was checked for medical accuracy by our review board before publishing
Finally, as with many database studies, the length of follow-up was relatively short in our study
Due to an aptly named phenomenon called dumping syndrome, slowed digestion can lead to pressure in the upper gastrointestinal tract, which triggers a release of stool in the lower GI tract, causing loose stools
The second pathway is peripheral
